LY2119620 modulation depends on the signaling endpoint. In M2-expressing HEK293T cells, it increased ACh and iperoxo potency, while high concentrations enhanced maximal β-arrestin-2 recruitment and reduced maximal Gαqi-linked IP-1 responses. In a separate purified M2/GoA assay, 100 μM LY2119620 reduced agonist-stimulated GTP turnover. [3]
In isolated mouse ventricular cardiomyocytes, 10 μM LY2119620 combined with 10 μM carbachol increased RyR2 Ser-2808 phosphorylation relative to carbachol alone. This result concerns a combination treatment in isolated cells. [4]
M2 receptor structure with iperoxo and LY2119620
Biochemical assay · Purified engineered human M2 receptor stabilized by Nb9-8; iperoxo-bound structures with and without LY2119620. [1]
LY2119620 occupied the extracellular vestibule above iperoxo. Its binding produced local pocket contraction and a Trp422 rotamer change, with few changes elsewhere.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 μM LY2119620 in crystallization overlay
- Method
- Lipidic cubic phase crystallization
- Co-treatment
- Iperoxo-bound receptor; Nb9-8 stabilization
- Reported limits
- Structural preparation concentration, not a potency estimate. Salt form and stock solvent not established.
Methods and source locations
Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620
Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.
Fig. 5; Extended Data Figs. 5–6; Extended Data Table 1; Online Methods: crystallization samples, crystallization and refinement
LY2119620 position and contacts: X-ray crystallography; ligand density and structural comparison. — Fig. 5b,c; Extended Data Fig. 5a; Allosteric modulation
Comparison with active receptor lacking modulator: Paired iperoxo-bound structures. — Extended Data Fig. 6a–d and caption; Allosteric modulation
M4 receptor–Gi complex with iperoxo and LY2119620
Biochemical assay · Engineered human M4 receptor with N-terminal BRIL fusion and ICL3 deletion, complexed with Gi and scFv16. [2]
LY2119620 bound the extracellular allosteric pocket, stacked between Phe186 and Trp435. The vestibule was more compact than in the iperoxo-only complex.
Literature-Reported Treatment Conditions
- Treatment concentration
- 337 μM LY2119620; 400 μM iperoxo added during final concentration
- Method
- Purified receptor–Gi complex for cryo-EM
- Co-treatment
- Iperoxo, Gi and scFv16
- Reported limits
- Structural preparation concentrations; no EC50 inferred. LY2119620 salt and stock solvent not established.
Methods and source locations
Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620
Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.
Figs. 1b,d and 2b–e; Results on binding/activation; Methods: construct design and M4R–Gi–scFv16 complex purification
LY2119620 binding pose at M4: Cryo-EM and comparison with iperoxo-only complex. — Fig. 2b,c,e; Results: Iperoxo and LY2119620 binding pockets in M4R
Pathway-dependent modulation of M2 signaling
Cell-based study · HEK293T cells expressing M2 receptor: hybrid Gαqi/IP-One and PathHunter β-arrestin-2 assays. [3]
LY2119620 increased agonist potency. At high concentrations it increased maximal β-arrestin-2 recruitment while reducing maximal IP-1 responses to ACh and iperoxo; modulator-only low-efficacy agonism was also observed.
Literature-Reported Treatment Conditions
- Treatment concentration
- LY2119620 0.1–100 μM; ACh or iperoxo concentration-response series
- Exposure duration
- 30 min modulator preincubation, followed by 90 min with agonist
- Method
- IP-One HTRF and PathHunter assays
- Vehicle
- Vehicle control; composition not specified in read assay methods
- Co-treatment
- ACh or iperoxo; modulator-only responses also shown
- Reported limits
- Methods list agonist ranges separately by assay. Exact per-condition n and SI Table 1 values not extracted. Fig. 1 caption: 3–14 independent experiments, mean ± SEM; methods: 4–8 IP-1 and 3–5 arrestin experiments, each in duplicate.
Methods and source locations
Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620
Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.
Fig. 1a,e–l; Results: Functional differences; Methods: G-protein IP-1 assay and β-arrestin recruitment assay
Agonist potency and maximal Gαqi-linked IP-1 response: IP-One HTRF; reference ACh maximum 100%, vehicle 0%. — Fig. 1e,f,i,j; functional Results; IP-1 methods
Maximal β-arrestin-2 recruitment: PathHunter complementation; basal activity 0%, reference ACh maximum 100%. — Fig. 1g,h,k,l; functional Results; β-arrestin recruitment methods
Purified-protein test of G-protein activation
Biochemical assay · Purified M2 receptor and heterotrimeric GoA; GTPase-Glo assay. Construct description is not fully reconciled between Results and linked preparation methods. [3]
At 100 μM, LY2119620 reduced agonist-stimulated GTP turnover relative to ACh or iperoxo alone in the purified-protein assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM LY2119620; 100 μM ACh or 10 μM iperoxo; M2R 1 μM, GoA 0.5 μM
- Exposure duration
- 90 min at room temperature (22–25°C)
- Method
- GTPase-Glo residual-GTP assay
- Co-treatment
- ACh or iperoxo; respective agonist-only controls and GoA-only reference
- Reported limits
- LY2119620 stock vehicle not specified. Single modulator concentration; no IC50 derived. Results call the purified receptor wild-type, while the referenced preparation method describes ICL3 truncation. No full-length/wild-type receptor claim is made.
Methods and source locations
Compound reported in the paper: LY2119620; Compound label in the paper: LY2119620
Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.
Fig. 1m and caption; Results: Functional differences; Methods: GTPase Glo assay
Agonist-stimulated GTP turnover: Luminescent residual-GTP assay with GoA-only reference. — Fig. 1m; functional Results; GTPase Glo methods
Carbachol-associated RyR2 phosphorylation in native cardiomyocytes
Cell-based study · Isolated wild-type mouse ventricular cardiomyocytes; isolation methods describe 3–6-month-old mice of either sex. [4]
LY2119620 plus carbachol increased RyR2 Ser-2808 phosphorylation relative to carbachol alone. This does not establish LY2119620 monotherapy activity or intact-animal benefit.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM LY2119620 with 10 μM carbachol
- Method
- Isolated cardiomyocyte treatment followed by Western blot
- Co-treatment
- Carbachol; untreated and carbachol-only controls
- Reported limits
- Exposure duration and vehicle not specified for Fig. 1 in read Western blot methods/caption. LY2119620 supplier, salt and purity not established.
Methods and source locations
Compound reported in the paper: LY2119620; Compound label in the paper: LY
Named experimental compound and stated model only; no salt conversion, batch equivalence or Adooq lot validation.
Fig. 1A–D; first Results paragraph; Methods: cardiomyocyte isolation and Western blot analyses
RyR2 Ser-2808 phosphorylation normalized to total RyR2: Phospho-specific/total RyR2 blot; GAPDH control. Caption: median ± S.D.; WT n = 5–7 mice, minimum 3 experiments/group. — Fig. 1C,D and caption; first Results paragraph; Western blot methods